|
|
|
|
|
by jpeloquin
1335 days ago
|
|
"To avoid losing power with multiple comparisons, we focus our analysis on the BsaI/BsmBI sites in SARS-CoV-2 and compare the BsaI/BsmBI map in SARS-CoV-2 to all other restriction maps of all other CoVs used in our analysis." It's important to know whether or not the authors picked BsaI & BmBI blind, before looking at the genome. If they picked BsaI & BmBI with knowledge of the SARS-CoV-2 genome, that doesn't dodge the multiple comparisons problem and the p-values aren't reliable. I guess it depends on how many other commonly used type IIS endonucleases there are. The authors use 214 to generate their null hypothesis distribution for the CoV restriction maps but say only 6 are specifically amenable to BAC cloning. The "wild type distribution" null distribution for fragment length (Figure 3C) being a simulation (permutation of known CoV genomes, split at randomly selected restriction sites) bothers me. On the first read I thought it was a distribution of fragment lengths in real viruses. Does synthesizing virtual genomes by permutation produce a realistic distribution of fragment lengths? |
|
BsaI has been used in high throughput assembly techniques such as Golden Gate assembly and Golden Braid assembly.
Golden Gate assembly is an extremely robust method for building modular genetic components. For example, one can create plasmids (circular pieces of DNA) with billions of variants of the spike proteins, each carrying a different combination of mutations. Then, those plasmids are transfected into corona viruses and incubated in a tissue culture. Now, one usually let natural selection do its thing and the most infective variants replicate in the tissue much faster and take over the population.
Having said all that, type 2s restriction sites usually are cut out during assembly so I'm not sure how having those is a good evidence for engineering. Actually, the opposite is true. Having none at all is one evidence which is very much suspicious